Literature DB >> 29404956

Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models.

Pablo Garrido-Gil1,2, Ana I Rodriguez-Perez1,2, Antonio Dominguez-Meijide1,2, Maria J Guerra1,2, Jose L Labandeira-Garcia3,4.   

Abstract

The exact mechanism of gut dysfunction in Parkinson's disease and, conversely, the role of gut pathology in brain dopaminergic degeneration are controversial. We investigated the effects of nigral lesions on the colonic neurotransmission, the effect of gut inflammation on the nigrostriatal dopaminergic function, and the possible involvement of the vagus nerve and the local renin-angiotensin system (RAS). Nigrostriatal dopamine depletion was performed by bilateral injection 6-hydroxydopamine, and gut inflammation was induced by dextran sulfate sodium salt treatment in rats and mice, respectively, with or without vagal disruption. A decrease in central dopamine levels induced a decrease in colonic dopamine types 1 and 2 receptor expression together with an increase in the colonic levels of dopamine and a decrease in the levels of acetylcholine, which may explain a decrease in gut motility. Central dopaminergic depletion also induced an increase in the colonic levels of inflammatory and oxidative stress markers together with activation of the pro-inflammatory arm of the local RAS. Mice with acute (1 week) or subchronic (3 weeks) gut inflammation did not show a significant increase in colonic α-synuclein and phosphorylated α-synuclein expression during this relatively short survival period. Interestingly, we observed early changes in the nigrostriatal dopaminergic homeostasis, dopaminergic neuron death, and increased levels of nigral pro-inflammatory markers and RAS pro-inflammatory activity. The present results show that a dysregulation of the neural bidirectional gut-brain interaction may explain the early gut disturbances observed in parkinsonian patients, and also the increase in vulnerability of nigral dopaminergic neurons after gut inflammation.

Entities:  

Keywords:  Angiotensin; Gastrointestinal; Inflammation; Neurodegeneration; Parkinson; Synuclein

Mesh:

Substances:

Year:  2018        PMID: 29404956     DOI: 10.1007/s12035-018-0937-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  77 in total

1.  Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections.

Authors:  Ayse Ulusoy; Robert J Phillips; Michael Helwig; Michael Klinkenberg; Terry L Powley; Donato A Di Monte
Journal:  Acta Neuropathol       Date:  2016-12-23       Impact factor: 17.088

2.  Vagotomy and subsequent risk of Parkinson's disease.

Authors:  Elisabeth Svensson; Erzsébet Horváth-Puhó; Reimar W Thomsen; Jens Christian Djurhuus; Lars Pedersen; Per Borghammer; Henrik Toft Sørensen
Journal:  Ann Neurol       Date:  2015-07-17       Impact factor: 10.422

3.  Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease.

Authors:  S J Qualman; H M Haupt; P Yang; S R Hamilton
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

4.  No direct projection is observed from the substantia nigra to the dorsal vagus complex in the rat.

Authors:  Zhi-Yong Wang; Hui Lian; Qing-Qing Cai; Hai-Yan Song; Xiao-Li Zhang; Li Zhou; Yi-Min Zhang; Li-Fei Zheng; Jin-Xia Zhu
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

5.  Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.

Authors:  Kathleen M Shannon; Ali Keshavarzian; Ece Mutlu; Hemraj B Dodiya; Delia Daian; Jean A Jaglin; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2011-07-15       Impact factor: 10.338

6.  Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death.

Authors:  Rita Valenzuela; Pedro Barroso-Chinea; Begoña Villar-Cheda; Belen Joglar; Ana Muñoz; Jose L Lanciego; Jose L Labandeira-Garcia
Journal:  J Neuropathol Exp Neurol       Date:  2010-11       Impact factor: 3.685

7.  Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis.

Authors:  Manabu Okawada; Hiroyuki Koga; Scott D Larsen; Hollis D Showalter; Anjanette J Turbiak; Xiaohong Jin; Peter C Lucas; Elke Lipka; John Hillfinger; Jae Seung Kim; Daniel H Teitelbaum
Journal:  Dig Dis Sci       Date:  2011-03-12       Impact factor: 3.199

8.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis.

Authors:  H S Cooper; S N Murthy; R S Shah; D J Sedergran
Journal:  Lab Invest       Date:  1993-08       Impact factor: 5.662

Review 9.  Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation.

Authors:  G Natale; L Pasquali; S Ruggieri; A Paparelli; F Fornai
Journal:  Neurogastroenterol Motil       Date:  2008-07       Impact factor: 3.598

10.  Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo.

Authors:  D C Brown; L J Steward; J Ge; N M Barnes
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more
  30 in total

Review 1.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

Review 2.  Is Gut Dysbiosis an Epicenter of Parkinson's Disease?

Authors:  Charul Rajput; Alika Sarkar; Nidhi Sachan; Neeraj Rawat; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2021-01-05       Impact factor: 3.996

Review 3.  Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

Authors:  Malvyne Rolli-Derkinderen; Laurène Leclair-Visonneau; Arnaud Bourreille; Emmanuel Coron; Michel Neunlist; Pascal Derkinderen
Journal:  J Neurol       Date:  2019-04-12       Impact factor: 4.849

Review 4.  Inflammatory Animal Models of Parkinson's Disease.

Authors:  Juan García-Revilla; Antonio J Herrera; Rocío M de Pablos; José Luis Venero
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 5.  The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease.

Authors:  Runing Yang; Ge Gao; Hui Yang
Journal:  Front Aging Neurosci       Date:  2022-06-24       Impact factor: 5.702

Review 6.  Gut microbiome-mediated regulation of neuroinflammation.

Authors:  John W Bostick; Aubrey M Schonhoff; Sarkis K Mazmanian
Journal:  Curr Opin Immunol       Date:  2022-04-21       Impact factor: 7.268

7.  A Gutsy Move for Cell-Based Regenerative Medicine in Parkinson's Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity.

Authors:  Jea-Young Lee; Julian P Tuazon; Sydney Corey; Brooke Bonsack; Sandra Acosta; Jared Ehrhart; Paul R Sanberg; Cesario V Borlongan
Journal:  Stem Cell Rev Rep       Date:  2019-10       Impact factor: 6.692

8.  Maackiain Ameliorates 6-Hydroxydopamine and SNCA Pathologies by Modulating the PINK1/Parkin Pathway in Models of Parkinson's Disease in Caenorhabditis elegans and the SH-SY5Y Cell Line.

Authors:  Rong-Tzong Tsai; Chia-Wen Tsai; Shih-Ping Liu; Jia-Xin Gao; Yun-Hua Kuo; Pei-Min Chao; Huey-Shan Hung; Woei-Cherng Shyu; Shinn-Zong Lin; Ru-Huei Fu
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

9.  Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death.

Authors:  Ana I Rodriguez-Perez; Diego Sucunza; Maria A Pedrosa; Pablo Garrido-Gil; Jaime Kulisevsky; Jose L Lanciego; Jose L Labandeira-Garcia
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

10.  Molecular neuro-biological and systemic health benefits of achieving dopamine homeostasis in the face of a catastrophic pandemic (COVID- 19): A mechanistic exploration.

Authors:  B W Downs; K Blum; D Bagchi; S Kushner; M Bagchi; J M Galvin; McG Lewis; D Siwicki; R Brewer; B Boyett; D Baron; J Giordano; R D Badgaiyan
Journal:  J Syst Integr Neurosci       Date:  2020-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.